1. Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillarin antibodies
- Author
-
David Goncalves, Nicole Fabien, Grace Kim, Fabrece Roup, Chelsea Bentow, Boaz Palterer, Marvin J. Fritzler, Michael Mahler, and Danilo Villalta
- Subjects
0301 basic medicine ,Male ,Chromosomal Proteins, Non-Histone ,Inflammatory bowel disease ,Gastroenterology ,Serology ,0302 clinical medicine ,Child ,Fluorescent Antibody Technique, Indirect ,Aged, 80 and over ,Immunoassay ,medicine.diagnostic_test ,biology ,IIf ,Middle Aged ,Prognosis ,Healthy Volunteers ,Rheumatoid arthritis ,Antibodies, Antinuclear ,Systemic sclerosis ,Female ,Original Article ,Antibody ,Adult ,medicine.medical_specialty ,Adolescent ,Immunology ,Multi-analyte ,Diagnosis, Differential ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,Humans ,Aged ,Autoantibodies ,030203 arthritis & rheumatology ,Autoimmune disease ,Scleroderma, Systemic ,business.industry ,Autoantibody ,Correction ,medicine.disease ,030104 developmental biology ,Case-Control Studies ,biology.protein ,Feasibility Studies ,Reagent Kits, Diagnostic ,business - Abstract
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease associated with several anti-nuclear antibodies (ANA), including those in the classification criteria (anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA Pol III). However, the presence of less common antibodies such as anti-fibrillarin (U3-RNP) that generate a clumpy nucleolar pattern by HEp-2 indirect immunofluorescence assay (IFA, ICAP AC-9) are considered disease specific and are with clinical subsets of SSc, therefore playing a role in diagnosis and prognosis. A specific and sensitive anti-fibrillarin assay would be an important addition to serological diagnosis and evaluation of SSc. The goal of this study was to evaluate a new particle-based multi-analyte technology (PMAT) for the measurement of anti-fibrillarin antibodies. A total of 149 patient samples were collected including 47 samples from France (Lyon and Paris, n = 32) and Italy (Careggi Hospital, Florence, n = 15) selected based on AC-9 HEp-2 IFA staining (> 1:640, clumpy nucleolar pattern) and 102 non-SSc controls (inflammatory bowel disease (IBD) n = 20, Sjögren’s syndrome (SjS) n = 20, infectious disease (ID) n = 7, systemic lupus erythematosus (SLE) n = 17, rheumatoid arthritis (RA) n = 17, and healthy individuals (HI) n = 21). All samples were tested on the anti-fibrillarin PMAT assay (research use only, Inova Diagnostics, USA). Additionally, the 47 anti-fibrillarin positive samples were also tested on PMAT assays for detecting other autoantibodies in ANA-associated rheumatic diseases (AARD). Anti-fibrillarin antibody data performed by fluorescence enzyme immunoassay (FEIA, Thermo Fisher, Germany) was available for 34 samples. The anti-fibrillarin PMAT assay was positive in 31/32 (96.9%, France) and 12/15 (80.0%, Italy) of samples preselected based on the AC-9 IIF pattern (difference p = 0.09). Collectively, the PMAT assay showed 91.5% (95% confidence interval (CI): 80.1–96.6%) sensitivity with 100.0% (95% CI: 96.4–100.0%) specificity in non-SSc controls. Strong agreement was found between PMAT and FEIA with 100.0% positive qualitative agreement (34/34) and quantitative agreement (Spearman’s rho = 0.89, 95% CI: 0.77.9–0.95%, p
- Published
- 2021